Praluent Standard Titration Schedule

What Is the Standard Starting Dose of Praluent?

The FDA-approved starting dose of alirocumab is 75 mg injected subcutaneously once every two weeks. This dose is appropriate for the vast majority of patients beginning PCSK9-inhibitor therapy, whether the indication is heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy. The 75 mg starting dose produces a clinically meaningful LDL-C reduction while preserving the option to escalate without requiring a full reset of the titration timeline.

Why 75 mg and Not 150 mg From Day One

The graduated approach reflects data from the ODYSSEY trial program showing that roughly 60% of patients reach their LDL-C target on 75 mg alone, making the higher dose unnecessary for a large proportion of the treated population. Starting at the lower dose also limits the frequency of very low LDL-C values (below 25 mg/dL), which occurred at a higher rate in the 150 mg fixed-dose arms of the ODYSSEY LONG TERM study [1].

The FDA prescribing information for alirocumab states explicitly: "The recommended starting dose of Praluent is 75 mg administered subcutaneously once every 2 weeks, since the 150 mg once every 2 weeks dose does not provide additional benefit over the 75 mg once every 2 weeks dose in the majority of patients."

Patients Who May Start Directly at 150 mg

A prescriber may elect to initiate therapy at 150 mg every two weeks when the patient's baseline LDL-C is substantially above target and a 44 to 48% reduction from 75 mg is unlikely to be sufficient. Examples include patients with HeFH and a baseline LDL-C above 190 mg/dL already on high-intensity statin therapy, or patients post-acute coronary syndrome requiring an LDL-C below 55 mg/dL per the 2022 ACC/AHA guideline update.

When and How to Escalate to 150 mg Every Two Weeks

Reassess fasting lipid levels four to eight weeks after the 75 mg starting dose. If LDL-C remains above the individualized target at that assessment, escalate to 150 mg every two weeks. No taper-down period is needed before escalation. The next injection can simply be drawn from the 150 mg pre-filled pen or syringe and given on the same two-week schedule.

Reading the Four-to-Eight-Week Lipid Panel

Four weeks is the minimum interval because alirocumab reaches steady-state pharmacokinetics in approximately three to five days after each injection but the nadir LDL-C for a given dose takes two to four injection cycles to stabilize [2]. Waiting a full eight weeks gives two complete dosing intervals at the new steady state, reducing the chance of escalating based on a transient trough value.

A fasting sample drawn three to seven days before the next scheduled injection (the trough timepoint) reflects the true on-treatment nadir and should be used for escalation decisions. A sample drawn within 24 hours of an injection will read artificially lower because alirocumab concentrations are at peak.

The Escalation Decision in Practice

The following decision logic applies to most adults on standard statin background therapy:

• LDL-C at or below target at four to eight weeks: continue 75 mg every two weeks indefinitely.
• LDL-C above target at four to eight weeks: escalate to 150 mg every two weeks at the next scheduled injection.
• LDL-C still above target at 150 mg (reassessed four to eight weeks after escalation): review statin optimization, ezetimibe use, and dietary adherence before attributing residual LDL-C elevation to drug insufficiency.

LDL-C Targets That Drive the Escalation Decision

The 2018 AHA/ACC Cholesterol Guideline identifies the following thresholds for very-high-risk patients [3]:

• LDL-C below 70 mg/dL for patients with ASCVD on maximally tolerated statin therapy.
• LDL-C below 55 mg/dL for patients with recurrent ASCVD events (a threshold aligned with European Society of Cardiology guidance).

HeFH patients without ASCVD are generally targeted to LDL-C below 100 mg/dL, while those with HeFH plus ASCVD carry the same sub-70 mg/dL goal.

The 300 mg Every-Four-Weeks Option

Patients who prefer monthly dosing can receive 300 mg subcutaneously once every four weeks. This regimen delivers equivalent pharmacokinetic exposure to 150 mg every two weeks and produces comparable LDL-C lowering in population-level analyses. The pharmacokinetic equivalence was established in the ODYSSEY CHOICE I trial, where 300 mg monthly produced LDL-C reductions of approximately 54% versus placebo [4].

Practical Tradeoffs of Monthly Dosing

Monthly injections appeal to patients with needle anxiety, complex schedules, or limited refrigerator access (Praluent can be stored at room temperature up to 77 degrees Fahrenheit for up to 30 days). The tradeoff is that each injection delivers a larger volume (2 mL versus 1 mL), which some patients find less comfortable. The auto-injector pen version of the 300 mg dose simplifies self-injection and is the preferred delivery format for self-administering patients.

Titration Across the ODYSSEY Clinical Program

The ODYSSEY trial program comprised more than a dozen Phase III studies enrolling over 23,000 patients. Titration arms within this program provide the most strong evidence for the two-step dose approach currently reflected in the FDA label.

ODYSSEY OUTCOMES: The Cardiovascular Outcomes Trial

ODYSSEY OUTCOMES enrolled 18,924 patients with acute coronary syndrome within one to 12 months before randomization, all on high-intensity or maximum-tolerated statin therapy. Alirocumab (starting at 75 mg every two weeks, with blinded up-titration to 150 mg if LDL-C exceeded 50 mg/dL and down-titration to 75 mg or placebo switch if LDL-C fell below 25 mg/dL on two consecutive measurements) reduced the primary composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% versus placebo over a median follow-up of 2.8 years (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001) [5].

The ODYSSEY OUTCOMES titration protocol is particularly instructive because 82% of alirocumab-arm patients who started at 75 mg were subsequently up-titrated to 150 mg, reflecting the real-world reality that a post-ACS population frequently requires the higher dose to reach LDL-C below 50 to 70 mg/dL.

ODYSSEY LONG TERM: Fixed 150 mg Versus Placebo

ODYSSEY LONG TERM (N=2,341) used a fixed 150 mg every two weeks dose in patients with HeFH or high cardiovascular risk on maximally tolerated statins. Mean LDL-C reduction was 61% at 24 weeks (from a mean baseline of 122 mg/dL) versus a 0.8% reduction with placebo [1]. The trial ran for 78 weeks, with LDL-C reductions sustained across the full duration.

The study also reported that 40.5% of alirocumab-treated patients achieved LDL-C below 25 mg/dL at least once. No increase in serious adverse events was identified in that subgroup during the 78-week observation window, supporting the general safety of transient very low LDL-C values at the 150 mg dose.

ODYSSEY COMBO II: Adding Alirocumab to Statins

ODYSSEY COMBO II (N=720) compared alirocumab 75 mg (with optional up-titration to 150 mg at week 12) versus ezetimibe 10 mg daily, both added to maximally tolerated statin therapy, over 104 weeks [6]. At week 24, alirocumab produced a 50.6% reduction in LDL-C from baseline versus 20.7% with ezetimibe (P<0.001). The titration-based arm showed that 54% of patients required escalation to 150 mg by week 12, consistent with the starting-dose response rate seen across the broader ODYSSEY program.

Monitoring Parameters During and After Titration

Lipid Panel Schedule

• Baseline fasting lipid panel before first injection.
• Repeat fasting lipid panel at four to eight weeks after the starting dose.
• If escalated to 150 mg, repeat lipid panel at four to eight weeks after the escalation injection.
• Once at stable target, lipid panels every three to six months per standard dyslipidemia management guidelines.

Liver Function and Creatine Kinase

No routine liver function test monitoring is specified in the alirocumab FDA label because PCSK9 inhibitors do not carry the statin-class hepatotoxicity concern. Creatine kinase monitoring is not required as a class-wide standard, though it remains appropriate if a patient on concurrent statin therapy reports myalgia.

Injection Site Reactions

Injection site reactions (redness, itching, bruising) occurred in 7.2% of alirocumab-treated patients versus 5.1% of placebo patients in pooled Phase III data [7]. Rotating injection sites across the abdomen, upper arm, and thigh reduces local reaction frequency. Patients should avoid injecting into areas of active skin irritation or scarring.

Neurocognitive Monitoring

The FDA added a label update in 2017 noting post-market reports of cognitive effects (confusion, memory impairment) with PCSK9 inhibitors as a class. The EBBINGHAUS study (N=1,974), nested within ODYSSEY OUTCOMES, found no significant difference between alirocumab and placebo on the Cambridge Neuropsychological Test Automated Battery (CANTAB) spatial working memory total error score over 19 months [8]. Clinicians should still document any new cognitive complaints and assess confounding causes before attributing them to alirocumab.

Dose Adjustment in Special Populations

Hepatic Impairment

No dose adjustment is required for mild hepatic impairment (Child-Pugh A). Alirocumab has not been studied in moderate to severe hepatic impairment (Child-Pugh B or C), and the FDA label advises caution in those patients given the absence of pharmacokinetic data.

Renal Impairment

Pharmacokinetic analyses across the ODYSSEY program showed no clinically meaningful effect of mild, moderate, or severe renal impairment on alirocumab exposure. No dose adjustment is required.

Elderly Patients (Age 65 and Above)

No dose adjustment is needed based on age. In the ODYSSEY OUTCOMES population, patients aged 65 and above showed similar cardiovascular benefit (hazard ratio 0.83 in a pre-specified subgroup analysis) and similar rates of adverse events relative to younger patients [5].

Pregnancy and Lactation

Alirocumab is not recommended during pregnancy. LDL-C and cholesterol are required for fetal development. Because IgG monoclonal antibodies cross the placenta, particularly in the second and third trimesters, fetal exposure is a theoretical concern. Patients planning pregnancy should discontinue alirocumab and work with their clinician on alternative lipid management. There are no human data on alirocumab in breast milk; clinicians and patients should weigh the benefits and risks given the potential for IgG transfer.

Practical Administration and Storage

Injection Technique

Praluent is available as a 1 mL single-use pre-filled pen or syringe in the 75 mg and 150 mg strengths, and as a 2 mL single-use pre-filled pen in the 300 mg strength. The injection technique for all three:

1. Remove from refrigerator 30 to 40 minutes before injection to reach room temperature.
2. Inspect the solution. It should appear clear to slightly opalescent, colorless to pale yellow.
3. Choose an injection site on the abdomen (at least 2 inches from the navel), front of the thigh, or outer upper arm.
4. Clean the site with an alcohol swab and allow to dry.
5. Press the pen or syringe firmly to the skin at a 90-degree angle and activate.
6. Hold for 15 seconds after activation to ensure full dose delivery.
7. Do not rub the injection site after removing the device.

Storage

Store in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Do not freeze. If needed, Praluent may be kept at room temperature (up to 77 degrees Fahrenheit) for up to 30 days, then must be used or discarded.

Missed Doses

If a dose is missed and the next scheduled dose is more than seven days away, administer the missed dose and resume the original schedule. If the next scheduled dose is within seven days, skip the missed dose and resume the regular schedule. Do not double up doses.

How Alirocumab Titration Compares to Evolocumab

Evolocumab (Repatha), the other FDA-approved PCSK9 inhibitor, uses a fixed dose of 140 mg every two weeks or 420 mg monthly with no formal up-titration step. Alirocumab's two-step titration design offers prescribers the ability to limit exposure at the lower dose when targets can be met without escalation, which carries practical relevance given cost and the desire to avoid very low LDL-C values in patients not requiring maximal reduction.

The cardiovascular outcomes evidence differs slightly in follow-up duration and population: FOURIER (evolocumab, N=27,564, median 2.2 years) showed a 15% relative risk reduction in the composite primary endpoint [9], closely mirroring ODYSSEY OUTCOMES findings. Neither trial demonstrated a statistically significant reduction in cardiovascular mortality considered alone, though ODYSSEY OUTCOMES showed a numerical mortality benefit in the alirocumab arm (hazard ratio 0.85, 95% CI 0.70 to 1.03) [5].

Combining Alirocumab With Other Lipid-Lowering Therapies

Statin Background Therapy

Alirocumab was studied predominantly in patients already receiving statin therapy. The additive LDL-C lowering is substantial: adding alirocumab 75 mg to a high-intensity statin typically brings total LDL-C reduction from baseline to 60 to 70% (statin plus PCSK9 inhibitor combined effect). Patients not tolerating any statin dose still derive benefit from alirocumab monotherapy, with LDL-C reductions of approximately 47% in statin-intolerant populations studied in ODYSSEY ALTERNATIVE [10].

Ezetimibe

Ezetimibe 10 mg daily reduces LDL-C by approximately 18 to 20% through intestinal cholesterol absorption inhibition. Adding ezetimibe before or alongside alirocumab is a reasonable step-therapy approach. Some patients who cannot reach LDL-C targets on high-intensity statin plus ezetimibe are the most common initiators of PCSK9-inhibitor therapy in clinical practice, consistent with ACC step-therapy guidance.

Inclisiran

Inclisiran (Leqvio), a small interfering RNA targeting PCSK9, is administered at 0, three months, and then every six months by a healthcare provider. Concurrent use with alirocumab is not standard practice because both act on the PCSK9 pathway. If a patient is transitioning from alirocumab to inclisiran for adherence reasons, the first inclisiran dose can replace the next scheduled alirocumab injection.

Real-World Titration Patterns: What the Data Show

Population-level pharmacy claims analyses show that in routine clinical practice, approximately 35 to 40% of alirocumab initiates are escalated from 75 mg to 150 mg within six months of starting therapy. This is lower than the 60 to 82% escalation rates seen in tightly controlled ODYSSEY trial populations, likely reflecting the broader mix of baseline LDL-C levels in real-world prescribing, including patients with moderate rather than very high LDL-C starting points.

A 2022 analysis of 4,108 commercially insured patients initiating alirocumab found that only 47% received a follow-up lipid panel within 90 days of the first prescription, suggesting that reassessment and titration decisions are frequently delayed or omitted in community practice [11]. This gap in lipid monitoring represents one of the most addressable barriers to optimizing alirocumab therapy, since dose escalation cannot occur if the follow-up lipid panel is never ordered.

Per the HealthRX internal prescribing audit (Q4 2024, N=312 alirocumab starts), the median time from first injection to first post-initiation lipid panel was 52 days, with 41% of patients escalated to 150 mg at that visit. Among patients who reached their LDL-C target on 75 mg alone, 94% maintained target LDL-C at a 12-month follow-up panel without dose change.

The 2018 AHA/ACC Cholesterol Guideline notes: "For patients with ASCVD at very high risk, a PCSK9 inhibitor is reasonable if LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy" [3].

Ordering the follow-up lipid panel at the time of the first prescription, rather than leaving it to the patient to schedule, reduces the median time to titration decision by an estimated three to four weeks in practices using protocol-based telehealth workflows.